Alimera Sciences Inc. (ALIM)

Business: Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally.

IPO Date: 22-Apr-2010

Non-Exec. Chairman & Consultant: Mr. Charles Daniel Myers

Pres, CEO & Director: Mr. Richard S. Eiswirth Jr.

Listing: NASDAQ: ALIM

Country: United States

Headquarters: Alpharetta, GA

Website: https://alimerasciences.com

Market cap: $36.77 Mln

Revenue (TTM): $59.71 Mln

Earnings (TTM): $-6.68 Mln

Cash: $9.95 Mln

Total Debt: $43.60 Mln

Insider's Holding: 22.51%

Liquidity: Low

52 Week range: $3.94 - 9.79

Shares outstanding: 7,002,960

10 Years Aggregate:

• CFO: $-187.76 Mln
• EBITDA: $-155.95 Mln
• Net Profit: $-224.24 Mln